Gewinnerbranchen der Jahre 2006 bis 2040 (Seite 883)

[gast77]

Antwort auf Beitrag Nr.: 60.514.635 von clearasil am 08.05.19 11:16:32

Hallo Clearasil
Herzlichen Glückwunsch zu Deiner Arbeit hier. Bist sehr stark engagiert und bringst viel Gutes zu Tage.

Danke auch dazu dass Du mich zu CRY überredet hast Stand heute 22% plus. Ein paar dicke Daumen für Dich
Allerdings liegt meine EnWave bei +50%

Bei Wasserstoff biste ja mit Powercell 1:0 in Führung gegangen, aber wir werden sehen: es ist ja noch nicht einmal Halbzeit.
Grüße gast77

[clearasil]

Antwort auf Beitrag Nr.: 60.514.569 von clearasil am 08.05.19 11:09:33

zu Nel Asa

NEL - Aussichtsreiche Zukunftstechnologie

Das norwegische Technologieunternehmen NEL erforscht Wasserstofftechniken und vermarktet derartige Produkte. Das Ziel ist es, im Rahmen der Anwendungen den benötigten Wasserstoff aus erneuerbaren Energiequellen herzustellen. Wasserstoff hat den Vorteil, dass im Gegensatz zur reinen Elektromobilität keine so teuren und schweren Batterien zur Energiespeicherung benötigt werden und ist insbesondere für "grössere" Anwendungen in der Industrie sowie im Einsatz bei Schiffen, Bussen oder LKWs interessant.

Es besteht eine Kooperation mit Nikola Motors, einem Hersteller für Elektro-Lastkraftwagen, welche mit einer Kombination aus Brennstoffzellen und kleineren Batterien betrieben werden. Zuletzt gab der Energiekonzern Wattenfall bekannt, im Rahmen des Joint Ventures Hybrit Development an Wasserstoff Elektrolyse Anlagen zu forschen für die NEL das notwendige Know-How bereitstellen könnte. Aufgrund der immer strengeren Umweltauflagen und tendenziell niedrigeren Schadstoffausstossrichtlinien beschäftigen sich immer mehr Konzerne mit Wasserstofftechnologie. Trotz des bereits gut gelaufenen Aktienkurses ist die NEL Aktie sehr attraktiv und nach wie vor zu billig. Ein weiteres unterbewertetes Unternehmen ist die MBH Corporation.

Webseite des Unternehmens: https://www.nelhydrogen.com

[clearasil]

Antwort auf Beitrag Nr.: 60.514.419 von clearasil am 08.05.19 10:54:12

aus twitter:

$VCEL MDWD down over 10%,indicates who got better deal perhaps?

ich sehe das genau so.

[clearasil]

zu VCEL - bin hier weiter sehr zuversichtlich, Guidance leicht angehoben, ab jetzt wird jedes Quartal stärker werden, hohe Biopsien-Zahlen für Maci, die in Behandlungen münden werden.

so funkioniert NexoBrid, das durch eine Einlizenzierung erworbene Erweiterungsprodukt zu Epicel:

Turning to NexoBrid, as we have mentioned, approximately 40,000 patients are hospitalized in the U.S. each year, most of whom require debridement of burn eschar to facilitate healing and reduce the risk of infection. Surgical excision of eschar is currently the standard of care and is performed through repeated use of a large surgical blade to remove necrotic tissue into a bleeding healthy tissue is reached. NexoBrid is a topically administered biological product that informatically removes eschar in patients with deep partial and full thickness burns within 4 hours of application without harming viable tissue. In January, MediWound announced positive top line results from the pivotal Phase 3 DETECT study of NexoBrid in adult patients with deep, partial and full thickness thermal burns up to 30% of total body surface area. The study met its primary endpoint of complete eschar removal as well as all secondary endpoints, including shorter time to eschar removal, a lower incidence of surgical eschar removal and lower blood loss compared to standard of care. A key safety endpoint non-inferiority and time to complete wound closure compared to standard of care was also achieved.

+++ The positive events in the Phase 3 DETECT trial announced last January were likely not surprising to any investigator – any investigator involved in the trial, because NexoBrid efficacy is so clear. Hard, leathery, dead tissue is liquefied 4 hours and it can easily be wiped away with a tongue depressor. The intact skin remains completely unharmed and intact. It is important to note that the trial was rigorously controlled to manage. And I expected this trial when it’s published to become a landmark paper in my field. I am confident then approved the real world clinical results will be consistent with both the DETECT trial results in my own clinical experience. We have been into consistently and selectively to debris, burn, eschar in one 4-hour application. It’s a dramatic improvement over our current standard of care.

For the first time, we have the ability to completely remove all the eschar early after injury without the risk of collateral damage or injury to nearby vital tissues, blood vessels or nerves and all in 4 hours. There is no other enzymatic debridement product in the market that it brings as quickly as selectively as NexoBrid and it really puts us in a class of its own. There is no question that it will change the standard of care for burn injured patients in the U.S. In fact, every physician I know that has used it in Europe with already approved, believe it should be the standard of care for excision of burn eschar. European consensus guidelines on [indiscernible] eschar removal, has already been published. NexoBrid would definitely change my treatment algorithms as it is such an obvious and dramatic improvement on the antiquated techniques that we use today. Early eschar removal is a critical component to the initial care of the burn patient and a standard of care in developed countries. Burn eschar is essentially dead necrotic tissue, such as skin fat and muscle and eschar can serve as a source for bacteria and other microorganisms that can cause life threatening infections and as they released a number of circulating inflammatory mediators that have a number of well-known negative systemic effects. The number cause of death after burn injury is infection. And my first and primary goal of treating infection even before antibiotics is that of source control. In a burn patient, complete source control can only be achieved or obtained with removal of all necrotic, nonviable tissue eschar.



alles andere hier:
https://seekingalpha.com/article/4261334-vericel-corporation…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/article/4261334-vericel-corporation…

in diesem Zusammenhang auch interessant die Mutterfirma hinter NexoBrid, die die weltweit-rechte behalten haben - MediWound/MDWD:
https://www.marketscreener.com/MEDIWOUND-LTD-16056541/?type_…" target="_blank" rel="nofollow ugc noopener">
https://www.marketscreener.com/MEDIWOUND-LTD-16056541/?type_…

[clearasil]

zu NVTA - mit den zu erwartenden (angekündigten) schwachen Zahlen, aber yoy-growth: 47 %, hohe Kosten im ersten Quartal durch Sondereinflüsse.

unschön: verlieren noch Geld mit jedem Test - das muss sich ändern. Investieren agressiv in die Zukunft, burn rate wird sich weiter erhöhen.

+++

Given the pushback and roadblocks we encountered when we started the company we are proud to have grown from just 229 samples and few hundred thousand dollars revenue in 2013 to more than 300,000 samples and $148 million in revenue in 2018 and we expect to deliver more than 500,000 samples and more than $220 million in revenue this year.

+++

The results of this quarter, reflecting our continued execution give us confidence that we are on track to exceed our 2019 guidance. We are one step closer to our aspiration of serving more than one million patients and generating more than $500 million in revenue in 2020 and ultimately making genetic information a part of mainstream medical care for all.

+++ Second, we did see some headwinds including our Medicare rates were reduced under PAMA by the annual 10% cutback starting January 1, adjustments to expected payments from acquisition-related reproductive tests and we reviewed the institutional pharma buckets and determined that we needed to reduce the expected collections due to payer mix changes within the category.

+++ In the first quarter of 2019, we reduced COGS to an average cost per sample of $226 down from $279 in the first quarter of 2018 representing a 19% reduction year-over-year. Our cost of goods was essentially flat in absolute dollars compared to the prior quarter and yet we accessioned nearly 7,000 more tests this quarter. This shows the power of increasing volume. For COGS volume is critical. By continuing to contain and reduce COGS we have more ability to work on the pricing side of the equation and still maintain our target 50% gross margin.

On the fourth quarter call, we indicated that we would increase our burn due to two factors. First, the Q1 is always a high burn quarter for us due to annual costs on big-ticket items occurring in the first quarter. And second, that our personnel costs would increase as we felt the full effect of bringing on employees late last year and early this year in sales and R&D to hit our aggressive volume and revenue growth goals. Both bore out.

Finally, we enhanced our cash position ending the quarter with cash, cash equivalents, restricted cash and marketable securities with $287.1 million. So why the raise? Our main rationale for our March raise was to fund the further acceleration of our investments in some very specific areas as we transform the genetics industry. We raised nearly $197 million in gross proceeds and our cash position sits at over $287 million at quarter end. So we are well funded for the foreseeable future.


https://seekingalpha.com/article/4261277-invitae-corporation…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/article/4261277-invitae-corporation…

[clearasil]

CVRS - earnings call Q 1 19
https://seekingalpha.com/article/4261237-corindus-vascular-r…" target="_blank" rel="nofollow ugc noopener">
https://seekingalpha.com/article/4261237-corindus-vascular-r…

+++ Let me start with some key highlights of the quarter that reflect the momentum we are seeing in 2019. Revenue was $3 million roughly double the $1.5 million of revenue in the first quarter of last year. We received purchase orders for 11 CorPath GRX systems including one purchased upgrade and installed nine GRX systems bringing our total installed base up to 61 systems.

We sold a record 602 single use cassettes in Q1 generating sales of nearly $300,000 which continues to affirm growing adoption and utilization of the robot. We received CE mark for our neurovascular indication allowing us to sell neurovascular robots in 33 countries. In February, we submitted for premarket clearance of our neurovascular indication or CorPath GRX with the FDA.

+++ And finally as announced previously we completed a $19.8 million private placement in Q1 with a large new institutional investor Capital World and existing stockholders Hudson Executive and BioStar Ventures. These proceeds will support our ongoing development efforts.

+++ The rising interest is evident in the growing number of purchase orders for the CorPath GRX, 11 orders were placed in Q1, 10 new systems and one upgrade. This represents an increase of 83% over Q4 of last year at a 267% increase over purchase orders in the first quarter of last year. These numbers tell us that more facilities are initiating robotic programs.

The record number of cassettes sold in the first quarter further speaks to greater utilization of the system already in place. Overall there were more procedures done using the CorPath GRX than ever before.

Another notable trend during the quarter was the increased enrollment in service agreements which are normally priced at approximately 10% of our capital equipment selling price on a per year per robot basis. Service revenue added $300,000 to our revenue during the quarter significantly exceeding our internal expectations.

+++ As mentioned earlier, we recently completed the first clinical robotic assisted PCI procedures in Japan, marking initial enrollment in a post-market study of CorPath GRX. The addition of the CE Mark for neurovascular treatment will enable us to expand our opportunities in the European markets.

+++ And just recently we received an order for the first CorPath GRX system in Italy and also launching in Australia and building out our presence in India and Singapore. 2019 has the potential to be a year of significant growth for us in markets outside the U.S.

Hospitals today are starting to think about remote differently. As the Clinique Pasteur example I just show a demonstrates remote is happening today while we work on the enhancements of remote capabilities for the future, as a follow on to the successful telerobotic study we did at the Apex Heart Institute in India last December, we're conducting beta test with Verizon on their 5G network.

+++ For the balance of 2019, we're focused on the following goals; continuing to work towards FDA clearance of CorPath GRX for neurovascular applications, conducting the first neuro clinical case in Europe, submitting the next wave of CorPath GRX automation to the FDA for clearance, adding initiation of a clinical trial for remote intervention and completing a potential partnership agreement to co-develop and commercialize the neurovascular robot.

[anyway]

Es tut sich was beim Thema Brennstoffzellen:
https://www.ise.fraunhofer.de/de/forschungsprojekte/litefcbi…

[clearasil]

Antwort auf Beitrag Nr.: 60.506.202 von Rastelly am 07.05.19 14:57:59

hi rastelly - bislang keine meinung und nicht auf der watch - was gefällt dir an dova?

[Rastelly]

DOVA PHARMACEUTICALS INC (DOVA)

Nach der Abstrafung in 2018 von 35 US $ und im Dezember rutscht der Kurs auf 7 US $.

Es könnte sich ein Boden bilden in den letzten 6 Monaten.

Ihr Produkt für Thrombopenie (sehr seltene Krankheit) = zu wenig Blutplättchen hat natürlich nicht den grossen Kundenkreis.

Die gestrigen Zahlen wurden positiv aufgenommen, mit Nachhaltigkeit?

https://finance.yahoo.com/news/dova-pharmaceuticals-1q-earni…

Bestehen Meinungen oder bei jemand auf der Watchliste?

Gruss RS

[clearasil]

Quotes Charts News Ratings Calendar Company Financials Consensus Revisions
News Summary Most relevant All news Official Publications Sector news MarketScreener Strategies Analyst Recommendations
Novartis : A $2 Million Drug Is About to Hit the Market
share with twitter share with LinkedIn share with facebook share via e-mail


0
05/07/2019 | 05:45am EDT

By Denise Roland

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them.

Novartis AG has yet to set a price for the gene therapy called Zolgensma, but executives say the drug's potential to cure spinal muscular atrophy, an inherited disease that typically kills babies before they turn two, justifies a seven-figure price.

Gene therapies target diseases that result from a faulty gene by introducing a working version into the body. They are attracting interest, both for their ability to cure otherwise devastating illnesses in one treatment and also for their high cost. Luxturna, the only gene therapy on sale in the U.S. so far to treat a form of inherited sight loss, costs $850,000 a patient.

"A therapy is useless if no one can afford it," said Cathryn Donaldson, a spokeswoman for America's Health Insurance Plans, an industry association. She said members want to encourage innovation but that high prices are a problem.

The issue is gaining in importance as more gene therapies go on sale. The Food and Drug Administration expects to approve 10 to 20 gene and cell therapies a year by 2025.

Zolgensma is expected to go on sale soon, with an FDA decision due this month. The treatment tackles spinal muscular atrophy, whose sufferers lack a gene essential for muscle control. Without treatment, victims of the most severe form typically die before their second birthday, making SMA the most common genetic cause of infant death. Between 400 and 500 babies are born with SMA every year in the U.S., around 300 of whom have the most severe version.

All 12 babies treated in Zolgensma's first clinical trial have passed their second birthday, with most hitting key milestones like holding up their heads, eating by mouth and sitting unaided.
https://www.marketscreener.com/NOVARTIS-9364983/news/Novarti…" target="_blank" rel="nofollow ugc noopener">
https://www.marketscreener.com/NOVARTIS-9364983/news/Novarti…